Skip to main content
MedicHelpLine
Join Free
Verified Professional Network190+ CountriesHIPAA-Aware Platform
Back to Drug Index
General MedicationsORALStandard

PAZOPANIB HYDROCHLORIDE

PAZOPANIB HYDROCHLORIDE

Standard Dose
EQ 200MG BASE
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary

Approval overview PAZOPANIB HYDROCHLORIDE is listed in Drugs@FDA under application 219034 (ANDA).

Review priority: STANDARD Marketing status: Prescription Active ingredient PAZOPANIB HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 200MG BASE Sponsor EUGIA PHARMA Submission history Latest submission status date: 2024-12-04 00:00:00.

Structured Monograph

Clinical summary

Approval overview PAZOPANIB HYDROCHLORIDE is listed in Drugs@FDA under application 219034 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient PAZOPANIB HYDROCHLORIDE Form and strength TABLET;ORAL - EQ 200MG BASE Sponsor EUGIA PHARMA Submission history Latest submission status date: 2024-12-04 00:00:00. Submission type: ORIG.

Monitoring

  • • Marketing status: Prescription
  • • Review priority: STANDARD

Interaction Notes

  • No interaction notes stored yet.